AR051638A1 - Compuestos de piperidinilo y su uso para tratar desordenes de respuesta al bloqueo de los canales de calcio tipo n - Google Patents
Compuestos de piperidinilo y su uso para tratar desordenes de respuesta al bloqueo de los canales de calcio tipo nInfo
- Publication number
- AR051638A1 AR051638A1 ARP050104312A ARP050104312A AR051638A1 AR 051638 A1 AR051638 A1 AR 051638A1 AR P050104312 A ARP050104312 A AR P050104312A AR P050104312 A ARP050104312 A AR P050104312A AR 051638 A1 AR051638 A1 AR 051638A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- hydrogen
- haloalkyl
- independently selected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Composiciones farmacéuticas que los contienen y usos. Reivindicacion 1: Un compuesto con la formula (1), o una sal, profármaco o solvato farmacéuticamente aceptable de él, en que: R1 y R2 se seleccionan cada uno independientemente del grupo consistente en hidrogeno, alquilo, haloalquilo, halogeno, alcoxi, haloalcoxi, ciano, nitro, amino e hidroxi; R3 se selecciona del grupo consistente en alquilo, alquenilo, cicloalquilo, cicloalquilalquilo, alcoxialquilo, hidroxialquilo, 2- tetrahidrofuranilo, 3-tetrahidrofuranilo, 2-tetrahidrofuranilalquilo, 3-tetrahidrofuranilalquilo, alquilsulfonilaminoalquilo y aminocarbonilalquilo; Z se selecciona del grupo consistente en Z1, Z2, Z3 y Z4, en que Z1 es una formula (2); Z2 es una formula (3); Z3 es -CR8R9-(CH2)o-D-R14; y Z4 es -SO2-R15; R4 y R5 se seleccionan cada uno independientemente del grupo consistente en hidrogeno, alquilo, alquenilo, hidroxialquilo, haloalquilo, alquiltiol, aminoalquilo fenilo; o R4 y R5 junto con el átomo de nitrogeno al que están unidos forman un anillo heterocíclico de 5 o 6 miembros en que uno o varios átomos de carbono del anillo heterocíclico son reemplazados opcionalmente con NR16, O, o S, en que R16 es hidrogeno o alquilo C1-3; R6 es hidrogeno y R7 se selecciona del grupo consistente en hidrogeno; alquilo; hidroxialquilo; alcoxialquilo; haloalquilo; aminoalquilo; cicloalquilo; fenilo sustituido opcionalmente con uno o dos sustituyentes seleccionados independientemente del grupo consistente en alquilo, cicloalquilo, halogeno, ciano, amino, alquilamino, dialquilamino, hidroxi, nitro, haloalquilo, y alcoxi; bencilo sustituido opcionalmente con uno o dos sustituyentes seleccionados independientemente del grupo consistente en alquilo, cicloalquilo, halogeno, ciano, amino, alquilamino, dialquilamino, hidroxi, nitro, haloalquilo, y alcoxi; y benciloxialquilo; o R6 y R7 junto con el átomo de carbono al que están unidos forman un grupo cicloalquilo C3-7; o R7 es hidrogeno; R4 es hidrogeno o alquilo C1-3; y R5 y R6 juntos forman un puente -CH2-CH2-CH2- o -CH2CHG1-CHG2-CH2-, en que G1 y G2 son ambos hidrogeno o junto con el átomo de carbono al que están unidos forman un grupo fenilo fundido; R8 y R9 son ambos hidrogeno o juntos forman =O; R10, R11, R12 y R13 se seleccionan cada uno independientemente del grupo consistente en hidrogeno, alquilo, alcoxi, halogeno, haloalquilo, hidroxi, hidroxialquilo, ciano, amino, aminoalquilo, alquilamino, y dialquilamino; R14 se selecciona del grupo consistente en fenilo sustituido opcionalmente con uno o dos sustituyentes seleccionados independientemente del grupo consistente en alquilo, alcoxi, halogeno, haloalquilo, hidroxi, hidroxialquilo, ciano, amino, aminoalquilo, alquilamino, y dialquilamino; naftilo sustituido opcionalmente con uno o dos sustituyentes seleccionados independientemente del grupo consistente en alquilo, alcoxi, halogeno, haloalquilo, hidroxi, hidroxialquilo, ciano, amino, aminoalquilo, alquilamino, y dialquilamino; quinolinilo; piridilo; y fenilo sustituido con fenilo, bencilo, fenoxi, o benciloxi, en que cada anillo fenilo está sustituido opcionalmente con uno o dos sustituyentes seleccionados independientemente del grupo consistente en halogeno, haloalquilo, alquilo, alcoxi, hidroxi, amino y ciano; y alquilo; R15 es fenilo o naftilo, cada uno de ellos sustituido opcionalmente con uno o dos sustituyentes seleccionados independientemente del grupo consistente en alquilo, alcoxi, halogeno, haloalquilo, amino, alquilamino y dialquilamino; A es O, CH2, o ausente (un enlace covalente), y B es CH, excepto cuando A esO, entonces R8 y R9 son ambos hidrogeno; o A-B es CH=C; D es C=O, -CH=CH-, o está ausente; m es 0 o 1; n es 0, 1, 2, 3, 4, o 5; y o es 0, 1, 2, o 3; con la condicion de que cuando Z es Z2, R3 es alquilo, R8 y R9 son ambos hidrogeno, A es CH2, B es CH y n es 1, entonces al menos uno de R10, R11, R12, o R13 es diferente de hidrogeno.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61841904P | 2004-10-14 | 2004-10-14 | |
US69497205P | 2005-06-30 | 2005-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR051638A1 true AR051638A1 (es) | 2007-01-31 |
Family
ID=35840205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050104312A AR051638A1 (es) | 2004-10-14 | 2005-10-14 | Compuestos de piperidinilo y su uso para tratar desordenes de respuesta al bloqueo de los canales de calcio tipo n |
Country Status (14)
Country | Link |
---|---|
US (1) | US9000174B2 (es) |
EP (1) | EP1814851B1 (es) |
JP (3) | JP2008516917A (es) |
KR (1) | KR20070063043A (es) |
AR (1) | AR051638A1 (es) |
AU (1) | AU2005293697A1 (es) |
BR (1) | BRPI0516351A (es) |
CA (1) | CA2582933A1 (es) |
ES (1) | ES2426006T3 (es) |
IL (1) | IL182434A0 (es) |
NO (1) | NO20072432L (es) |
PE (1) | PE20060977A1 (es) |
TW (1) | TW200630337A (es) |
WO (1) | WO2006040181A2 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200630337A (en) * | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
US8247442B2 (en) | 2006-03-29 | 2012-08-21 | Purdue Pharma L.P. | Benzenesulfonamide compounds and their use |
WO2007118853A1 (en) * | 2006-04-13 | 2007-10-25 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use as blockers of calcium channels |
US8937181B2 (en) * | 2006-04-13 | 2015-01-20 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
US8399486B2 (en) | 2007-04-09 | 2013-03-19 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use thereof |
WO2008143263A1 (ja) * | 2007-05-22 | 2008-11-27 | Astellas Pharma Inc. | 1位置換テトラヒドロイソキノリン化合物 |
JP5380435B2 (ja) * | 2007-05-31 | 2014-01-08 | ユーロ−セルティーク ソシエテ アノニム | アミド化合物およびその使用 |
US8563732B2 (en) | 2007-05-31 | 2013-10-22 | Shionogi & Co., Ltd. | Oxyimino compounds and the use thereof |
WO2009040659A2 (en) * | 2007-09-28 | 2009-04-02 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
JP5656158B2 (ja) * | 2008-03-05 | 2015-01-21 | 国立大学法人金沢大学 | 再生組織用細胞内カルシウムイオンモニタリング装置 |
JP5501983B2 (ja) | 2008-06-11 | 2014-05-28 | 塩野義製薬株式会社 | オキシカルバモイル化合物およびその使用 |
GB0813144D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
GB0813142D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
WO2010014257A2 (en) * | 2008-08-01 | 2010-02-04 | Purdue Pharma L.P. | Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof |
CN102428069B (zh) | 2009-04-02 | 2014-04-02 | 盐野义制药株式会社 | 丙烯酰胺化合物及其用途 |
US9730941B2 (en) | 2012-06-07 | 2017-08-15 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the inhibition of Pin1 |
US9453002B2 (en) | 2013-08-16 | 2016-09-27 | Janssen Pharmaceutica Nv | Substituted imidazoles as N-type calcium channel blockers |
WO2016011265A2 (en) | 2014-07-17 | 2016-01-21 | Beth Israel Deaconess Medical Center, Inc. | Biomarkers for pin1-associated disorders |
US10548864B2 (en) | 2015-03-12 | 2020-02-04 | Beth Israel Deaconess Medical Center, Inc. | Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions |
JP6086960B2 (ja) * | 2015-08-20 | 2017-03-01 | Necトーキン株式会社 | 入力装置 |
US20210128537A1 (en) * | 2016-12-21 | 2021-05-06 | Praxis Precision Medicines, Inc. | T-type calcium channel modulators and methods of use thereof |
WO2021007487A1 (en) | 2019-07-11 | 2021-01-14 | Praxis Precision Medicines, Inc. | Formulations of t-type calcium channel modulators and methods of use thereof |
WO2023047107A1 (en) * | 2021-09-22 | 2023-03-30 | The University Of Durham | Aryl or heteroaryl derived compounds for the treatments of microbial infections |
Family Cites Families (178)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1445595A (en) | 1973-09-06 | 1976-08-11 | Wyeth John & Brother Ltd | 4-aminoquinoline derivatives and intermediates for their pre paration |
GB1482099A (en) | 1974-12-11 | 1977-08-03 | Wyeth John & Brother Ltd | Sulphonamido derivatives |
US4131680A (en) * | 1974-12-11 | 1978-12-26 | John Wyeth & Brother Ltd. | Hypotensive sulphonamidopiperidyl indoles |
DE2718405A1 (de) | 1977-04-26 | 1978-11-02 | Boehringer Sohn Ingelheim | Neue n- eckige klammer auf 1-(3-benzoylpropyl)-4-piperidyl eckige klammer zu -sulfonsaeureamide und verfahren zu deren herstellung |
IN148482B (es) | 1977-06-03 | 1981-03-07 | Pfizer | |
JP2641070B2 (ja) * | 1988-12-06 | 1997-08-13 | 富士写真フイルム株式会社 | ハロゲン化銀カラー写真感光材料 |
US4990523A (en) | 1989-06-19 | 1991-02-05 | A. H. Robins Company, Incorporated | Treatment of chronic inflammatory joint disease with arylsulfonamides |
JPH05201971A (ja) | 1992-01-28 | 1993-08-10 | Hokuriku Seiyaku Co Ltd | 環状アミン含有ベンゼンスルホンアミド誘導体 |
US5177217A (en) | 1992-04-27 | 1993-01-05 | Warner-Lambert Company | Process for the manufacture of (S)-3-amino-1-substituted-pyrrolidines |
US5723490A (en) | 1992-09-08 | 1998-03-03 | Vertex Pharmaceuticals Incorporated | THF-containing sulfonamide inhibitors of aspartyl protease |
US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
IL115420A0 (en) | 1994-09-26 | 1995-12-31 | Zeneca Ltd | Aminoheterocyclic derivatives |
TW406075B (en) | 1994-12-13 | 2000-09-21 | Upjohn Co | Alkyl substituted piperidinyl and piperazinyl anti-AIDS compounds |
US5696267A (en) | 1995-05-02 | 1997-12-09 | Schering Corporation | Substituted oximes, hydrazones and olefins as neurokinin antagonists |
US5688960A (en) | 1995-05-02 | 1997-11-18 | Schering Corporation | Substituted oximes, hydrazones and olefins useful as neurokinin antagonists |
WO1996038471A1 (en) | 1995-05-29 | 1996-12-05 | Pfizer Inc. | Dipeptides which promote release of growth hormone |
ES2247604T3 (es) * | 1995-06-12 | 2006-03-01 | G.D. SEARLE & CO. | Composiciones que comprenden un inhibidor de ciclooxigenasa-2 y un inhibidor de 5-lipoxigenasa. |
ES2186803T3 (es) * | 1995-10-05 | 2003-05-16 | Darwin Discovery Ltd | Peptidos tio-sustituidos como inhibidores de metaloproteinasas y de la liberacion de tnf. |
US6124341A (en) * | 1996-02-13 | 2000-09-26 | Abbott Laboratories | Endothelin antagonists |
US5827875A (en) * | 1996-05-10 | 1998-10-27 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
WO1997045119A1 (en) | 1996-05-24 | 1997-12-04 | Novartis Ag | Use of substance p antagonists for treating social phobia |
US20020128476A1 (en) | 1996-08-08 | 2002-09-12 | Smithkline Beecham Corporation | Inhibitors of cysteine protease |
US6281227B1 (en) * | 1996-12-13 | 2001-08-28 | Aventis Pharma Deutschland Gmbh | Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds |
US5972963A (en) * | 1996-12-23 | 1999-10-26 | Hoechst Marion Roussel, Inc. | 3-aryl-2-(1-substituted 4-piperidinyl)-1,1-dioxo-3H-benzo[D]isothiazoles and related compounds |
US6376506B1 (en) | 1997-01-23 | 2002-04-23 | Syntex (U.S.A.) Llc | Sulfamide-metalloprotease inhibitors |
ZA98376B (en) | 1997-01-23 | 1998-07-23 | Hoffmann La Roche | Sulfamide-metalloprotease inhibitors |
GB9714129D0 (en) | 1997-07-04 | 1997-09-10 | Pfizer Ltd | Azetidines |
US6136827A (en) | 1997-07-25 | 2000-10-24 | Merck & Co., Inc. | Cyclic amine modulations of chemokine receptor activity |
EP1031563B1 (en) | 1997-09-30 | 2005-12-28 | Daiichi Pharmaceutical Co., Ltd. | Sulfonyl derivatives |
US6130220A (en) | 1997-10-16 | 2000-10-10 | Syntex (Usa) Inc. | Sulfamide-metalloprotease inhibitors |
US6750228B1 (en) * | 1997-11-14 | 2004-06-15 | Pharmacia Corporation | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
TR200002182T2 (tr) | 1998-01-27 | 2000-12-21 | Aventis Pharmaceuticals Products Inc. | İkame edilmiş aksozaherosayklil faktör xa inhibitörleri |
AU3408999A (en) | 1998-03-06 | 1999-09-20 | Janssen Pharmaceutica N.V. | Glycine transport inhibitors |
GB9805520D0 (en) | 1998-03-17 | 1998-05-13 | Zeneca Ltd | Chemical compounds |
KR20010042851A (ko) * | 1998-04-20 | 2001-05-25 | 후지야마 아키라 | cGMP 포스포디에스터라제 억제자로서의 안트라닐산유도체 |
US6303620B1 (en) | 1998-05-11 | 2001-10-16 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
US6387897B1 (en) | 1998-06-30 | 2002-05-14 | Neuromed Technologies, Inc. | Preferentially substituted calcium channel blockers |
US6011035A (en) | 1998-06-30 | 2000-01-04 | Neuromed Technologies Inc. | Calcium channel blockers |
US6492375B2 (en) | 1998-06-30 | 2002-12-10 | Neuromed Technologies, Inc. | Partially saturated calcium channel blockers |
US6310059B1 (en) | 1998-06-30 | 2001-10-30 | Neuromed Technologies, Inc. | Fused ring calcium channel blockers |
US6423519B1 (en) | 1998-07-15 | 2002-07-23 | Gpc Biotech Inc. | Compositions and methods for inhibiting fungal growth |
US6316623B1 (en) | 1998-08-21 | 2001-11-13 | Isis Pharmaceuticals, Inc. | Ethylenediamine compound libraries |
HUP0100819A3 (en) * | 1998-10-16 | 2002-12-28 | Daiichi Asubio Pharma Co Ltd | Aminophenoxyacetic acid derivatives as neuroprotectants and pharmaceutical compositions containing them |
US6267945B1 (en) | 1998-12-18 | 2001-07-31 | Neuromed Technologies, Inc. | Farnesol-related calcium channel blockers |
US6248739B1 (en) * | 1999-01-08 | 2001-06-19 | Pharmacia & Upjohn Company | Quinolinecarboxamides as antiviral agents |
AUPP818099A0 (en) | 1999-01-14 | 1999-02-11 | Fujisawa Pharmaceutical Co., Ltd. | New n-containing heterocyclic compounds |
US6841552B1 (en) * | 1999-05-05 | 2005-01-11 | Ortho-Mcneil Pharmaceutical, Inc. | 3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl amine-derived neuropeptide Y receptors ligands useful in the treatment of obesity and other disorders |
KR20020002501A (ko) | 1999-05-13 | 2002-01-09 | 시오노 요시히코 | 당뇨병의 예방 또는 치료약 |
US6344358B1 (en) * | 1999-05-28 | 2002-02-05 | Fujisawa Pharmaceutical Co., Ltd. | Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property |
WO2000074679A1 (en) | 1999-06-04 | 2000-12-14 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
GB2352240A (en) | 1999-07-13 | 2001-01-24 | Lilly Co Eli | Novel sulphonamides useful in treating CNS disorders |
DE60023148T2 (de) * | 1999-07-28 | 2006-07-06 | Ortho-Mcneil Pharmaceutical, Inc. | Amine and amide als ligande für den neuropeptid-y y5 rezeptor, und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen |
US20020151712A1 (en) | 1999-09-14 | 2002-10-17 | Nan-Horng Lin | 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission |
AR025884A1 (es) | 1999-10-01 | 2002-12-18 | Takeda Pharmaceutical | Compuestos de amina ciclica, su produccion y su uso |
EP1249233B9 (en) | 1999-11-26 | 2009-08-05 | Shionogi & Co., Ltd. | Npyy5 antagonists |
FR2802206B1 (fr) | 1999-12-14 | 2005-04-22 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
US6797820B2 (en) | 1999-12-17 | 2004-09-28 | Vicuron Pharmaceuticals Inc. | Succinate compounds, compositions and methods of use and preparation |
WO2001044179A1 (en) | 1999-12-17 | 2001-06-21 | Versicor, Inc. | Novel succinate compounds, compositions and methods of use and preparation |
FR2804429B1 (fr) * | 2000-01-31 | 2003-05-09 | Adir | Nouveaux derives de 4-sulfonamides piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
KR20020069362A (ko) | 2000-01-20 | 2002-08-30 | 에자이 가부시키가이샤 | 함질소환 화합물 및 이들을 포함하는 의약 조성물 |
US6566356B2 (en) * | 2000-03-03 | 2003-05-20 | Aventis Pharma S.A. | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation |
US6355631B1 (en) | 2000-03-03 | 2002-03-12 | Aventis Pharma S.A. | Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation |
CA2403686C (en) | 2000-03-23 | 2010-01-26 | Merck & Co., Inc. | Substituted piperidines as melanocortin receptor agonists |
AU2001254546A1 (en) | 2000-04-20 | 2001-11-07 | Nps Allelix Corp. | Aminopiperidines |
US6683093B2 (en) * | 2000-05-12 | 2004-01-27 | Pharmacia Corporation | Aromatic sulfone hydroxamic acids and their use as protease inhibitors |
JP2001322977A (ja) | 2000-05-12 | 2001-11-20 | Kotobuki Seiyaku Kk | ピペコリン酸誘導体及びその製造方法並びにこれを含有する医薬組成物 |
GB0011838D0 (en) | 2000-05-17 | 2000-07-05 | Astrazeneca Ab | Chemical compounds |
EP1162194A1 (en) * | 2000-06-06 | 2001-12-12 | Aventis Pharma Deutschland GmbH | Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use |
JP2004501191A (ja) * | 2000-06-28 | 2004-01-15 | テバ ファーマシューティカル インダストリーズ リミティド | カルベジロール |
HUP0300721A3 (en) * | 2000-07-26 | 2006-02-28 | Smithkline Beecham Plc | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity, process for producing them, pharmaceutical compositions containing them and use thereof |
US20020055457A1 (en) | 2000-08-07 | 2002-05-09 | Janus Todd J. | Methods of treating cancer and the pain associated therewith using endothelin antagonists |
JP2004509108A (ja) | 2000-09-14 | 2004-03-25 | シェーリング コーポレイション | 置換尿素神経ペプチドyy5受容体アンタゴニスト |
US6894063B2 (en) * | 2000-09-14 | 2005-05-17 | Schering Corporation | Substituted urea neuropeptide Y Y5 Receptor antagonists |
AU2001291830A1 (en) | 2000-09-25 | 2002-04-02 | Actelion Pharmaceuticals Ltd. | Substituted amino-aza-cycloalkanes useful against malaria |
US20020091114A1 (en) * | 2000-10-04 | 2002-07-11 | Odile Piot-Grosjean | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity |
US20020094989A1 (en) * | 2000-10-11 | 2002-07-18 | Hale Jeffrey J. | Pyrrolidine modulators of CCR5 chemokine receptor activity |
DE10058461A1 (de) | 2000-11-24 | 2002-09-19 | Bayer Ag | Substituierte Cyclohexanderivate und ihre Verwendung |
IT1320862B1 (it) | 2000-12-19 | 2003-12-10 | Bottero Spa | Convogliatore a tapparelle per l'avanzamento di lastre di vetro in unamacchina di molatura e macchina di molatura comprendente tale |
US6946476B2 (en) * | 2000-12-21 | 2005-09-20 | Schering Corporation | Heteroaryl urea neuropeptide Y Y5 receptor antagonists |
CA2432809C (en) | 2000-12-21 | 2010-11-30 | Schering Corporation | Heteroaryl urea neuropeptide y y5 receptor antagonists |
GB0101577D0 (en) * | 2001-01-22 | 2001-03-07 | Smithkline Beecham Plc | Compounds |
DE60219295T2 (de) | 2001-02-28 | 2008-01-03 | Merck & Co., Inc. | Acylierte piperidinderivate als melanocortin-4-rezeptoragonisten |
JP2004520423A (ja) | 2001-03-01 | 2004-07-08 | アストラゼネカ・アクチエボラーグ | Ccr5モジュレーターとしてのn−ピペリジニル化合物 |
CA2438272A1 (en) | 2001-03-02 | 2002-10-10 | John Macor | Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
US20040152692A1 (en) * | 2001-03-29 | 2004-08-05 | Dashyant Dhanak | Pyrrolidine sulfonamides |
EP1253723A1 (en) * | 2001-04-23 | 2002-10-30 | Lucent Technologies Inc. | Transmitter/receiver device with re-configurable output combining |
JP3834485B2 (ja) | 2001-05-28 | 2006-10-18 | 株式会社日立製作所 | レーザ駆動装置とそれを用いた光ディスク装置、及びそのレーザ制御方法 |
CA2450167A1 (en) * | 2001-06-12 | 2002-12-19 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
BR0210644A (pt) * | 2001-06-27 | 2004-07-20 | Smithkline Beecham Corp | Composto, formulação farmacêutica, método para inibir uma protease que cliva pós prolina/alanina, método para o tratamento ou profilaxia de distúrbios, e, uso do composto |
US20030006081A1 (en) | 2001-07-03 | 2003-01-09 | David Burke | Drive train and steering method and apparatus for race trucks |
IL159643A0 (en) * | 2001-07-26 | 2004-06-01 | Schering Corp | Substituted urea neuropeptide y y5 receptor antagonists |
EP1411944A1 (en) | 2001-08-03 | 2004-04-28 | Schering Corporation | Sulfonamide derivatives as gamma secretase inhibitors |
EP1283384A3 (en) | 2001-08-09 | 2004-08-11 | Smiths Wolverhampton Limited | Ballscrew locking nut |
JP2003081937A (ja) | 2001-09-07 | 2003-03-19 | Bayer Ag | ベンゼンスルホンアミド誘導体 |
WO2003024451A1 (de) | 2001-09-08 | 2003-03-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 2-(2-phenylethyl)-benzimidazol-5-carboxamid- derivative und ihre verwendung als tryptase_ inhibitoren |
WO2003024456A1 (en) | 2001-09-20 | 2003-03-27 | Eisai Co., Ltd. | Methods for treating and preventing migraines |
CN1582281A (zh) * | 2001-10-01 | 2005-02-16 | 大正制药株式会社 | Mch受体拮抗剂 |
MXPA04003858A (es) * | 2001-10-25 | 2004-07-08 | Schering Corp | Antagonistas de mch para el tratamiento de obesidad. |
MXPA04004956A (es) * | 2001-11-26 | 2004-08-11 | Schering Corp | Antagonistas de la hormona concentradora de melanina basados en la piperidina para tratamiento de la obesidad y de trastornos del sistema nervioso central. |
CA2837936A1 (en) | 2001-11-26 | 2003-06-05 | Trustees Of Tufts College | Peptidomimetic inhibitors of post-proline cleaving enzymes |
SI1499607T1 (sl) | 2001-12-04 | 2006-06-30 | Actelion Pharmaceuticals Ltd | 4-(piperidil- in pirolidil-alkil-ureido)-kinolinikot antagonisti receptorja urotensina II |
US7812035B2 (en) | 2001-12-11 | 2010-10-12 | Sepracor Inc. | 4-substituted piperidines, and methods of use thereof |
GB0130261D0 (en) | 2001-12-18 | 2002-02-06 | Pfizer Ltd | Lactams as tachykinin antagonists |
CN1816551A (zh) * | 2001-12-20 | 2006-08-09 | Osi药物公司 | 吡咯并嘧啶A2b选择性拮抗剂化合物,它们的合成及用途 |
AU2002365057A1 (en) * | 2001-12-21 | 2003-07-30 | Cytokinetics, Inc. | Compositions and methods for treating heart failure |
US6995144B2 (en) * | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
JP2005520522A (ja) | 2002-03-19 | 2005-07-14 | ノバルティス アクチエンゲゼルシャフト | 慢性神経痛の抑制に有用な化合物の同定方法およびその組成物 |
JPWO2003084542A1 (ja) | 2002-04-10 | 2005-08-11 | 藤沢薬品工業株式会社 | 神経栄養因子産生促進剤 |
DE10217006A1 (de) * | 2002-04-16 | 2003-11-06 | Merck Patent Gmbh | Substituierte Indole |
TW200409637A (en) * | 2002-06-26 | 2004-06-16 | Glaxo Group Ltd | Compounds |
AU2003258957A1 (en) * | 2002-06-27 | 2004-01-19 | Schering Corporation | Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity |
WO2004009549A2 (en) | 2002-07-18 | 2004-01-29 | Actelion Pharmaceuticals Ltd | Piperidines useful for the treatment of central nervous system disorders |
TW200401635A (en) * | 2002-07-23 | 2004-02-01 | Yamanouchi Pharma Co Ltd | 2-Cyano-4-fluoropyrrolidine derivative or salt thereof |
WO2004019940A1 (en) * | 2002-08-30 | 2004-03-11 | Pharmacia & Upjohn Company | Method of preventing or treating atherosclerosis or restenosis |
EP1554239B1 (en) | 2002-10-11 | 2011-01-26 | Actelion Pharmaceuticals Ltd. | Sulfonylamino-acetic acid derivatives and their use as orexin receptor antagonists |
SE0203752D0 (sv) | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
US7491827B2 (en) * | 2002-12-23 | 2009-02-17 | Millennium Pharmaceuticals, Inc. | Aryl sulfonamides useful as inhibitors of chemokine receptor activity |
AU2003303483A1 (en) | 2002-12-23 | 2004-07-22 | Millennium Pharmaceuticals, Inc. | Ccr8 inhibitors |
TW200510311A (en) | 2002-12-23 | 2005-03-16 | Millennium Pharm Inc | CCr8 inhibitors |
TW200505834A (en) | 2003-03-18 | 2005-02-16 | Sankyo Co | Sulfamide derivative and the pharmaceutical composition thereof |
TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
EP1613322A4 (en) * | 2003-04-11 | 2008-08-13 | Taigen Biotechnology Co Ltd | AMINOQUINOLINE COMPOUNDS |
US7049323B2 (en) * | 2003-04-25 | 2006-05-23 | Bristol-Myers Squibb Company | Amidoheterocycles as modulators of the melanocortin-4 receptor |
CN1226059C (zh) | 2003-05-21 | 2005-11-09 | 江西洪达医疗器械集团有限公司 | 自毁式安全注射器 |
US7405210B2 (en) * | 2003-05-21 | 2008-07-29 | Osi Pharmaceuticals, Inc. | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase |
MXPA05012899A (es) | 2003-05-30 | 2006-06-23 | Neuromed Tech Inc | 3-aminometil-pirrolidinas como bloqueadores del canal de calcio tipo n. |
WO2004111014A1 (en) | 2003-06-06 | 2004-12-23 | Vertex Pharmaceuticals Incorporated | Pyrimidine derivatives as modulators of atp-binding cassette transporters |
GB0314054D0 (en) | 2003-06-17 | 2003-07-23 | Pfizer Ltd | Amide derivatives as selective serotonin re-uptake inhibitors |
WO2005004497A1 (en) | 2003-07-04 | 2005-01-13 | Koninklijke Philips Electronics N.V. | Colour projection systems with improved lifetime |
GB0317315D0 (en) | 2003-07-24 | 2003-08-27 | Astex Technology Ltd | Pharmaceutical compounds |
ATE400272T1 (de) * | 2003-08-01 | 2008-07-15 | Chugai Pharmaceutical Co Ltd | Piperidin-verbindungen als malonyl-coa decarboxylase-hemmer |
KR101153335B1 (ko) | 2003-09-24 | 2012-07-05 | 메틸진 인코포레이티드 | 히스톤 데아세틸라제의 억제제 |
US7317025B2 (en) * | 2003-09-24 | 2008-01-08 | Johnson & Johnson Pharmaceutical Research & Development, Llc | Non-peptidic NPY Y2 receptor inhibitors |
ATE427748T1 (de) * | 2003-09-26 | 2009-04-15 | Actelion Pharmaceuticals Ltd | Pyridin-derivate und ihre verwendung als urotensin ii antagonisten |
US20050119266A1 (en) * | 2003-10-01 | 2005-06-02 | Yan Shi | Pyrrolidine and piperidine derivatives as factor Xa inhibitors |
GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
GB0326546D0 (en) * | 2003-11-14 | 2003-12-17 | Amersham Plc | Inhibitor imaging agents |
JP3687672B2 (ja) | 2003-11-25 | 2005-08-24 | 松下電工株式会社 | 粉末焼結部品の表面仕上げ方法 |
JP4380508B2 (ja) | 2003-11-28 | 2009-12-09 | 田辺三菱製薬株式会社 | 医薬組成物 |
JP2005154380A (ja) | 2003-11-28 | 2005-06-16 | Tanabe Seiyaku Co Ltd | ピペリジン誘導体 |
PE20050861A1 (es) * | 2003-12-03 | 2005-12-10 | Glaxo Group Ltd | Derivados de sales ciclicas de amonio cuaternario como antagonistas del receptor muscarinico de acetilcolina |
PL1723128T3 (pl) * | 2004-01-06 | 2013-04-30 | Novo Nordisk As | Pochodne heteroarylowe mocznika oraz ich zastosowanie jako aktywatory glukokinazy |
US7507760B2 (en) * | 2004-01-22 | 2009-03-24 | Neuromed Pharmaceuticals Ltd. | N-type calcium channel blockers |
US20050197336A1 (en) * | 2004-03-08 | 2005-09-08 | Miikana Therapeutics Corporation | Inhibitors of histone deacetylase |
EP1723102A2 (en) * | 2004-03-11 | 2006-11-22 | Elan Pharmaceuticals, Inc. | N-substituted benzene sulfonamides |
DE102004012070A1 (de) * | 2004-03-12 | 2005-09-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue cycloalkyl-haltige 5-Acylindolinone, deren Herstellung und deren Verwendung als Arzneimittel |
CN1972945A (zh) * | 2004-04-02 | 2007-05-30 | 腺苷治疗有限责任公司 | A2a腺苷受体的选择性拮抗剂 |
EP1735322B1 (en) | 2004-04-02 | 2011-09-14 | Novartis AG | Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful for the treatment of type 2 diabetes |
AU2005243188A1 (en) * | 2004-04-09 | 2005-11-24 | Millennium Pharmaceuticals, Inc. | Beta-carbolines useful for treating inflammatory disease |
KR20070044803A (ko) | 2004-04-09 | 2007-04-30 | 뉴로메드 파머큐티칼즈 리미티드 | 칼슘 채널 차단제로서 디아릴아민 유도체 |
US7880001B2 (en) * | 2004-04-29 | 2011-02-01 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
EA016138B1 (ru) * | 2004-06-17 | 2012-02-28 | Цитокинетикс, Инк. | Соединения, фармацевтические композиции и способы лечения сердечной недостаточности |
BRPI0512615A (pt) * | 2004-06-24 | 2008-03-25 | Shionogi & Co | compostos de sulfonamida |
JP2008512461A (ja) * | 2004-09-07 | 2008-04-24 | スミスクライン・ビーチャム・コーポレイション | 新規化合物 |
US8470829B2 (en) | 2004-09-09 | 2013-06-25 | Chugai Seiyaku Kabushiki Kaisha | Imidazolidine derivative and use thereof |
GB0420424D0 (en) | 2004-09-14 | 2004-10-20 | Ionix Pharmaceuticals Ltd | Therapeutic compounds |
JP2006083137A (ja) | 2004-09-17 | 2006-03-30 | Sankyo Co Ltd | 免疫抑制剤 |
JP2006083133A (ja) | 2004-09-17 | 2006-03-30 | Sankyo Co Ltd | スルファミド誘導体医薬組成物 |
TW200630337A (en) * | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
TW200843761A (en) * | 2004-10-28 | 2008-11-16 | Shionogi & Co | 3-carbamoyl-2-pyridone derivatives |
EP1702916A1 (en) | 2005-03-18 | 2006-09-20 | Santhera Pharmaceuticals (Schweiz) GmbH | DPP-IV inhibitors |
EP1863490A2 (en) * | 2005-03-28 | 2007-12-12 | Vertex Pharmaceuticals Incorporated | Muscarinic modulators |
JP5140577B2 (ja) | 2005-03-31 | 2013-02-06 | タケダ カリフォルニア インコーポレイテッド | ヒドロキシステロイドデヒドロゲナーゼ阻害剤 |
WO2006134481A1 (en) | 2005-06-16 | 2006-12-21 | Pfizer Inc. | Inhibitors of 11-beta hydroxysteroid dehydrogenase type 1 |
CN101212974A (zh) * | 2005-06-29 | 2008-07-02 | 默克公司 | 4-氟-哌啶t-型钙通道拮抗剂 |
WO2007052843A1 (ja) | 2005-11-04 | 2007-05-10 | Takeda Pharmaceutical Company Limited | 複素環アミド化合物およびその用途 |
PE20071092A1 (es) | 2005-12-08 | 2007-12-10 | Aventis Pharma Inc | Composicion farmaceutica que comprende un antagonista de cb1 y un agente antisicotico |
EP1965799A2 (en) | 2005-12-22 | 2008-09-10 | Merck & Co., Inc. | Substituted piperidines as calcium channel blockers |
US8247442B2 (en) * | 2006-03-29 | 2012-08-21 | Purdue Pharma L.P. | Benzenesulfonamide compounds and their use |
WO2007118853A1 (en) | 2006-04-13 | 2007-10-25 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use as blockers of calcium channels |
US8937181B2 (en) * | 2006-04-13 | 2015-01-20 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
JP2008044009A (ja) * | 2006-07-19 | 2008-02-28 | Honda Motor Co Ltd | 熱膨張係数が異なる部材の接合方法 |
BRPI0717742A2 (pt) | 2006-10-20 | 2013-11-26 | Arete Therapeutics Inc | Inibidores de epóxido hidrolase solúvel |
WO2008050200A1 (en) | 2006-10-24 | 2008-05-02 | Pfizer Products Inc. | Oxadiazole compounds as calcium channel antagonists |
CL2007003223A1 (es) | 2006-11-10 | 2008-01-11 | Wyeth Corp | Compuestos derivados de piperidinil 4-arilsulfonamidas n-sustituidas, que actuan como moduladores de la proteina sfrp-1; proceso para preparar los compuestos; co mposicion farmaceutica que comprende a dichos copmpuestos y uso de los compuestos para preparar medicamentos para el tratamiento de enfermedades. |
CN101622243B (zh) * | 2007-02-28 | 2013-12-04 | 旭化成制药株式会社 | 磺酰胺衍生物 |
US8399486B2 (en) * | 2007-04-09 | 2013-03-19 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use thereof |
WO2009040659A2 (en) | 2007-09-28 | 2009-04-02 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
-
2005
- 2005-10-05 TW TW094134846A patent/TW200630337A/zh unknown
- 2005-10-13 PE PE2005001210A patent/PE20060977A1/es not_active Application Discontinuation
- 2005-10-14 BR BRPI0516351-0A patent/BRPI0516351A/pt not_active IP Right Cessation
- 2005-10-14 KR KR1020077010938A patent/KR20070063043A/ko not_active Application Discontinuation
- 2005-10-14 ES ES05800452T patent/ES2426006T3/es active Active
- 2005-10-14 AU AU2005293697A patent/AU2005293697A1/en not_active Abandoned
- 2005-10-14 JP JP2007536110A patent/JP2008516917A/ja active Pending
- 2005-10-14 WO PCT/EP2005/011105 patent/WO2006040181A2/en active Application Filing
- 2005-10-14 AR ARP050104312A patent/AR051638A1/es not_active Application Discontinuation
- 2005-10-14 EP EP05800452.4A patent/EP1814851B1/en active Active
- 2005-10-14 CA CA002582933A patent/CA2582933A1/en not_active Abandoned
- 2005-10-14 US US11/665,345 patent/US9000174B2/en active Active
-
2007
- 2007-04-10 IL IL182434A patent/IL182434A0/en unknown
- 2007-05-10 NO NO20072432A patent/NO20072432L/no not_active Application Discontinuation
-
2011
- 2011-04-06 JP JP2011084148A patent/JP5554279B2/ja not_active Expired - Fee Related
-
2013
- 2013-11-21 JP JP2013241194A patent/JP2014065720A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP5554279B2 (ja) | 2014-07-23 |
CA2582933A1 (en) | 2006-04-20 |
JP2014065720A (ja) | 2014-04-17 |
PE20060977A1 (es) | 2006-10-12 |
US9000174B2 (en) | 2015-04-07 |
ES2426006T3 (es) | 2013-10-18 |
WO2006040181A3 (en) | 2006-11-09 |
TW200630337A (en) | 2006-09-01 |
JP2008516917A (ja) | 2008-05-22 |
KR20070063043A (ko) | 2007-06-18 |
US20090105249A1 (en) | 2009-04-23 |
BRPI0516351A (pt) | 2008-09-02 |
AU2005293697A1 (en) | 2006-04-20 |
EP1814851B1 (en) | 2013-06-05 |
JP2011173897A (ja) | 2011-09-08 |
WO2006040181A2 (en) | 2006-04-20 |
IL182434A0 (en) | 2007-07-24 |
EP1814851A2 (en) | 2007-08-08 |
NO20072432L (no) | 2007-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR051638A1 (es) | Compuestos de piperidinilo y su uso para tratar desordenes de respuesta al bloqueo de los canales de calcio tipo n | |
TW200643015A (en) | 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives | |
RU2495873C2 (ru) | Новое урациловое соединение или его соль, обладающие ингибирующей активностью относительно дезоксиуридинтрифосфатазы человека | |
AR049739A1 (es) | Derivados de aril-piridina | |
AR049696A1 (es) | Derivados de indol | |
AR057989A1 (es) | Derivados de indol-2-il-amida 1,5-sustituida. procesos de obtencion y composiciones farmaceuticas | |
AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
AR036042A1 (es) | Derivados aralquilsufonil-3-(pirrol-2-ilmetiliden)-2-indolinona, sus composiciones farmaceuticas y metodo para la modulacion de la actividad catalitica de una proteina quinasa | |
AR047538A1 (es) | Piridazinonas como antagonistas de las integrinas alfa4 | |
RS52397B (en) | PYRIDO / 2,1-A / ISOCHINOLINE DERIVATIVES AS DPP-IV INHIBITORS | |
AR058769A1 (es) | Inhibidores de peptidil-deformilasa(pdf),utiles para el tratamiento de la tuberculosis y composiciones farmaceuticas que los contienen. | |
DE69110320D1 (de) | Stickstoff enthaltende heterozyklische Verbindungen, ihre Herstellung und Verwendung. | |
HUP0402508A2 (hu) | 1,2,3,4-Tetrahidro-izokinolin-származékok mint urotenzin II receptor antagonisták és a vegyületeket tartalmazó gyógyszerkészítmények | |
HRP20140687T1 (hr) | Derivati benzofurana | |
CO5060482A1 (es) | Derivados terapeuticos de biarilo | |
MXPA05010816A (es) | Derivados de 4-(4- (heterociclilalcox}fenil)- 1-(heterociclil- carbonil) piperidina y compuestos relacionados como antagonistas de h3 de la histamina para el tratamiento de enfermedades neurologicas tales como alzheimer. | |
AR049092A1 (es) | Derivados de tetrahidronaftiridina como ligandos del receptor h3 de histamina | |
PE20090441A1 (es) | DERIVADOS DE IMIDAZO[1,2-a]PIRIDIN-2-ILMETIL PIPERIDINA SUSTITUIDA | |
AR036115A1 (es) | Compuesto de n-aroilaminas, composiciones farmaceuticas formuladas con dichos compuestos; uso de los compuestos mencionados en la preparacion de composiciones farmaceuticas para tratar,prevenir enfermedades o trastornos donde se requiere la aplicacion de antagonistas de receptores de la orexina huma | |
HK1110868A1 (en) | Heterocyclic compounds as ccr2b antagonists | |
PE20091429A1 (es) | 4-(4-ciano-2-tioaril)dihidropirimidinonas como inhibidores de la elastasa neutrofila humana (hne) | |
NO20025641D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
MEP12608A (en) | Derivatives of n-[phenyl (pyrrolidine-2-yl) methyl]benzamide and n-[(azepan-2-yl)phenylmethyl]benzamide, preparation method thereof and application of same in therapeutics | |
AR062965A1 (es) | Compuestos moduladores de receptores de glutamatometabotropicos mglur5, composiciones farmaceuticas que los contienen y usos terapeuticos en trastornos gastrointestinales, neurologicos y psiquiatricos agudos y cronicos | |
AR060593A1 (es) | 5-amido-2-carboxiamida-indoles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |